NASDAQ:BIOL - BIOLASE Stock Price, Forecast & News

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

BIOLASE's stock reverse split on the morning of Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split.

BIOLASE Inc (NASDAQ:BIOL) issued its earnings results on Wednesday, November, 6th. The medical technology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.13. The medical technology company earned $8.65 million during the quarter. BIOLASE had a negative net margin of 52.13% and a negative return on equity of 313.64%. View BIOLASE's Earnings History.

BIOLASE is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for BIOLASE.

4 equities research analysts have issued 1-year price objectives for BIOLASE's shares. Their forecasts range from $2.00 to $3.00. On average, they expect BIOLASE's share price to reach $2.50 in the next year. This suggests a possible upside of 223.4% from the stock's current price. View Analyst Price Targets for BIOLASE.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOLASE.

News articles about BIOL stock have been trending negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. BIOLASE earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned media coverage about the medical technology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for BIOLASE.

Some companies that are related to BIOLASE include Straumann (SAUHF), DENTSPLY SIRONA (XRAY), Sartorius (SARTF), SmileDirectClub (SDC), Biomerica (BMRA) and Remedent (REMI).

Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Magnachip Semiconductor (MX), Fluidigm (FLDM), NovaBay Pharmaceuticals (NBY), Vuzix (VUZI), Athersys (ATHX), Allena Pharmaceuticals (ALNA), Biocept (BIOC) and CTI BioPharma (CTIC).

BIOLASE's stock is owned by a number of of institutional and retail investors. Top institutional investors include Archon Capital Management LLC (8.65%) and Perkins Capital Management Inc. (4.26%). Company insiders that own BIOLASE stock include Garrett Sato, John R Beaver, Jonathan T Md Lord, Larry N Feinberg and Todd Norbe. View Institutional Ownership Trends for BIOLASE.

BIOL stock was acquired by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc. and Archon Capital Management LLC. Company insiders that have bought BIOLASE stock in the last two years include Garrett Sato, John R Beaver, Jonathan T Md Lord, Larry N Feinberg and Todd Norbe. View Insider Buying and Selling for BIOLASE.

Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BIOL stock can currently be purchased for approximately $0.77.

BIOLASE has a market capitalization of $23.93 million and generates $46.15 million in revenue each year. The medical technology company earns $-21,520,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. BIOLASE employs 190 workers across the globe.View Additional Information About BIOLASE.

The official website for BIOLASE is http://www.biolase.com/.

BIOLASE's mailing address is 4 Cromwell, Irvine CA, 92618. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]